Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Total Current Liabilities (2020 - 2025)

IceCure Medical (ICCM) has disclosed Total Current Liabilities for 6 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 12.51% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 12.51% year-over-year, with the annual reading at $4.8 million for FY2025, 12.51% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $4.8 million at IceCure Medical, down from $5.5 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $5.5 million in Q4 2024, with the low at $3.9 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $4.5 million, with a median of $4.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 42.44% in 2024, then fell 12.51% in 2025.
  • Over 5 years, Total Current Liabilities stood at $4.0 million in 2021, then grew by 7.86% to $4.3 million in 2022, then fell by 10.72% to $3.9 million in 2023, then skyrocketed by 42.44% to $5.5 million in 2024, then dropped by 12.51% to $4.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $4.8 million, $5.5 million, and $3.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.